Pulmonx Corporation (LUNG)

Market Cap	105.47M
Revenue (ttm)	87.47M
Net Income (ttm)	-57.09M
Shares Out	40.26M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35
Open	n/a
Previous Close	2.650
Day's Range	n/a
52-Week Range	2.500 - 9.370
Beta	0.45
Analysts	Buy
Price Target	11.53 (+340.08%)
Earnings Date	Jul 30, 2025

About LUNG

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 1, 2020
• Employees: 291
• Stock Exchange: NASDAQ
• Ticker Symbol: LUNG
• Website: https://pulmonx.com

Financial Performance

In 2024, Pulmonx's revenue was $83.79 million, an increase of 22.01% compared to the previous year's $68.68 million. Losses were -$56.39 million, -7.31% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $11.53, which is an increase of 340.08% from the latest price.

Price Target

$11.53

(340.08% upside)

Analyst Consensus: Buy